XBXiaoliang Bai

Xiaoliang Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoliang Bai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaojuan Zhu

    Department of Geriatrics, Baoding No.1 Central Hospital, Baoding, Hebei 071000, China

    2 shared publications
  • Fang Lu

    Department of Orthopedic, Baoding No. 1 Central Hospital, Baoding, China

    1 shared publication
  • Lei Yang

    Department of Anesthesiology, Baoding No. 1 Central Hospital, Baoding, China

    1 shared publication
  • Lili Hu

    Department of Respiratory Medicine, Laishui County Hospital, Baoding, China

    1 shared publication
  • Mingyuan Zhang

    Department of Rehabilitation, Laishui County TCM Hospital, Baoding, Hebei 074199, China

    1 shared publication
  • Shichao Liu

    Emergency Department, Baoding No. 1 Central Hospital, Baoding, China

    1 shared publication

Latest Publications

  • Open Access

    Emodin protects against apoptosis and inflammation by regulating reactive oxygen species-mediated NF-κB signaling in interleukin‐1β-stimulated human nucleus pulposus cells

    by Xiaojuan Zhu, Shuqin Guo, Mingyuan Zhang, Xiaoliang Bai

    Intervertebral disc degeneration (IDD) is a complex degradative disorder associated with inflammation. Emodin, an anthraquinone derivative, possesses strong anti-inflammatory activity. This study focused on the in vitro therapeutic action of emodin in a cellular model of IDD. Human nucleus pulposus cells (NPCs) were stimulated with interleukin‐1 β (IL-1 β) to induce inflammation. Cell Counting Kit-8 and terminal deoxynucleotidyl transferase dUTP nick end labeling staining assays were performed to evaluate the viability and apoptosis of NPCs, respectively. Caspase-3 activity was measured to indirectly assess cell apoptosis. Western blot analysis was performed to detect protein expression levels. Reverse transcription‐polymerase chain reaction was performed for the detection of relative mRNA levels of tumor necrosis factor- α (TNF- α) and IL-6. Enzyme-linked immunosorbent assay was performed to analyze TNF- α and IL-6 secretion. Our results showed that emodin treatment mitigated IL-1β-induced reduction of cell viability in NPCs. Moreover, the increase in reactive oxygen species (ROS) production, apoptotic rate, and caspase-3 activity in IL-1 β-stimulated NPCs was reduced by emodin treatment. Treatment with emodin also abolished IL-1 β-induced inflammation in NPCs, as indicated by reduced secretion of IL-6 and TNF- α. Besides, the increase in expression levels of phosphorylated p65 and nuclear p65 in IL-1 β-stimulated NPCs was suppressed by emodin treatment. Furthermore, inhibition of nuclear factor kappa B (NF- κB) activation with pyrrolidine dithiocarbamate aggravated the protective effects of emodin. These results suggested that emodin protected NPCs against IL-1 β-induced apoptosis and inflammation via inhibiting ROS-mediated activation of NF- κB.


  • Higenamine mitigates interleukin-1β-induced human nucleus pulposus cell apoptosis by ROS-mediated PI3K/Akt signaling

    by Xiaojuan Zhu, Shichao Liu, Zhijiao Cao, Lei Yang, Fang Lu, Yulan Li, Lili Hu, Xiaoliang Bai

    Intervertebral disc degeneration (IDD) is a natural problem linked to the inflammation. Higenamine exerts multiple pharmacological properties in inflammation-related disorders. Our study aimed to explore the function of higenamine on interleukin (IL)-1β-caused apoptosis of human nucleus pulposus cells (HNPCs). Cell apoptosis was investigated by TUNEL and flow cytometry. Apoptosis-related biomarkers were determined by qRT-PCR or Western blotting. The protein in the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling was measured by Western blotting. We found that higenamine showed little effect on cell apoptosis, but mitigated IL-1β-caused apoptosis in a dose-dependent pattern. Higenamine attenuated IL-1β-induced decrease of Bcl-2 and increase of Bax and cleaved caspase-3. Higenamine did not affect the reactive oxygen species (ROS) level and the PI3K/Akt signaling, but attenuated IL-1β-induced ROS production and inhibition of the PI3K/Akt signaling. IL-1β repressed the activation of the PI3K/Akt pathway, but ROS inhibition using N-acetylcysteine (NAC) rescued this pathway. The PI3K/Akt signaling suppression using LY294002 reversed the inhibitive effect of higenamine on IL-1β-caused apoptosis, and this effect was weakened by ROS inhibition. In conclusion, higenamine attenuates IL-1β-caused apoptosis of HNPCs via ROS-mediated PI3K/Akt pathway.